

Original Article

Response to fluoxetine in children and adolescents: a weighted gene co-expression network analysis of peripheral blood

Teresa Torres¹, Daniel Boloc², Natalia Rodríguez³, Ana Blázquez⁴, Maria Teresa Plana⁴, Eva Varela⁴, Patricia Gassó^{1,5}, Albert Martínez-Pinteño¹, Luisa Lázaro^{2,4,5,6}, Joan Albert Arnaiz^{1,5}, Sergi Mas^{1,5,6}

¹Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain; ²Department of Medicine, University of Barcelona, Barcelona, Spain; ³Fundació Clinic per la Recerca Biomèdica (FCRB), Barcelona, Spain; ⁴Department of Child and Adolescent Psychiatry and Psychology, Institute of Neurosciences, Hospital Clínic de Barcelona, Barcelona, Spain; ⁵The August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; ⁶Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Carlos III Health Institute, Madrid, Spain

Received September 27, 2019; Accepted February 13, 2020; Epub May 15, 2020; Published May 30, 2020

Abstract: The inconclusive and non-replicated results of pharmacogenetic studies of antidepressant response could be related to the lack of acknowledgement of its mechanism of action. In this scenario, gene expression studies provide an interesting framework to reveal new candidate genes for pharmacogenetic studies or peripheral biomarkers of fluoxetine response. We propose a systems biology approach to analyse changes in gene expression induced by eight weeks of treatment with fluoxetine in peripheral blood. 21 naïve child and adolescents participated in the present study. Our analysis includes the identification of gene co-expression modules, using Weighted Gene Co-expression Network Analysis (WGCNA), followed by protein-protein interaction (PPI) network construction coupled with functional annotation. Our results revealed two modules of co-expression genes related to fluoxetine treatment. The constructed networks from these modules were enriched for biological processes related to cellular and metabolic processes, cell communication, immune system processes, cell death, response to stimulus and neurogenesis. Some of these processes, such as immune system, replicated previous findings in the literature, whereas neurogenesis, a mechanism proposed to be involved in fluoxetine response, had been identified for the first time using peripheral tissues. In conclusion, our study identifies several biological processes in relation to fluoxetine treatment in peripheral blood, offers new candidate genes for pharmacogenetic studies and valuable markers for peripheral biomarker discovery.

Keywords: Selective serotonin reuptake inhibitors, pharmacogenomics, convergent functional genomics, gene expression, neurogenesis, children

Introduction

Between 40 and 50% of patients taking antidepressants relapse or do not respond to treatment [1]. Common genetic polymorphisms explain 42% of this variability in antidepressant response [2]. With some exceptions that include CYP2D6 and CYP2C19, included in guidelines from the Clinical Pharmacogenetics Implementation Consortium (CPIC) [3], pharmacogenetic research has so far failed to identify specific associations through either candidate gene approaches or genome-wide association studies (GWAS) [4].

Although some studies have detected significant associations with antidepressant treatment outcomes, very few of these results have been replicated in independent studies. The lack of replicated candidate gene studies has been attributed to a poor understanding of the biological mechanisms underlying treatment response, phenotypic variability and several limitations of pharmacogenetic studies: differences between studies in terms of design, statistical power, type and dosage of antidepressant and outcome assessment. Pharmacogenetic GWAS have provided tentative hits, but most associations have been inconclusive and

Gene expression changes induced by fluoxetine in children and adolescents

not replicated [5]. Unfortunately, despite the use of large cohorts from multicentric studies and consortia these studies are underpowered and have not revealed reliable predictors of treatment outcomes [2, 6, 7].

In this scenario, genome-wide gene expression studies may reveal the effects of both genetic background and environmental/epigenetic factors, thereby providing an interesting insight into this complex phenotype [8]. These studies make it possible to identify differentially expressed genes associated with antidepressant response that could be used as biomarkers of the phenotype. Numerous studies using this approach have been published, most of which have focused on analyzing the identification of predictor biomarkers by comparing gene expression between groups of responders and non-responders [9-12]. A few studies have also searched for moderator biomarkers by analyzing gene expression changes before and after antidepressant treatment [10, 11, 13-15]. Genome-wide expression analysis not only allows independent and isolated gene analysis to be carried out, but can also be used to explore the biological processes involved in the antidepressant response phenotype. In this regard, an interesting strategy for complex phenotypes involving numerous genes of small effect is the identification of gene co-expression networks (sets of genes that display correlated expressions). Only two studies have proposed this approach in the field of antidepressant response [14, 15].

In the present study, we propose a systems biology analytical approach, based on the identification of gene co-expression modules followed by protein-protein interaction (PPI) network construction and functional annotation analysis, of changes in gene expression induced by eight weeks of fluoxetine treatment in peripheral blood of drug-naïve child and adolescence, to identify biological processes related to fluoxetine treatment.

Materials and methods

Subjects

Twenty-one children and adolescents receiving fluoxetine treatment for the first time participated in the present study. Patients were diagnosed with major depressive disorder (MDD),

obsessive compulsive disorder (OCD) or generalized anxiety disorder (GAD) according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) [16]. The study was carried out at the Child and Adolescent Psychiatry and Psychology Department of the Institute of Neuroscience at Hospital Clínic, Barcelona. Exclusion criteria were comorbidity of the principal disorder with other psychiatric disorders, Tourette syndrome, autism, somatic disorders and neurological diseases, an intelligence quotient of <70 and non-white ethnicity. All procedures were approved by the hospital's ethics committee. Written informed consent was obtained from all parents and verbal informed consent was given by all subjects following an explanation of the procedures involved.

Information on illness severity was obtained during the initial phase of the study through the assessment of several scales: the Global Assessment of Functioning (GAF) scale [17]; the Children's Global Assessment Scale (CGAS) [18]; the Clinical Global Impression Severity scale (CGI-S) [19]; the Children's Depression Inventory (CDI) [20]; the Obsessive Compulsive Inventory, children's version (OCI-CV) [21]; and the Screen for Child Anxiety-Related Emotional Disorders (SCARED), children's version and parents' version [22]. To assess clinical improvement, these same scales were administered after eight weeks of fluoxetine treatment.

Expression study

RNA isolation and microarray hybridization

For each patient, two blood samples were collected in PAX gene Blood RNA Tubes (Qiagen, Valencia, CA, USA), one prior to the start of fluoxetine treatment and the second after eight weeks of continuous fluoxetine treatment. Plasma concentrations of fluoxetine (FLX) and its metabolite, norfluoxetine (NORFLX), were determined after eight weeks of fluoxetine treatment using a high-performance liquid chromatography method described previously [23]. Patients with concentrations of the active moiety (FLUOX+NORFLUOX) outside the therapeutic range (120-500 ng/mL) [24] were discarded.

Total RNA was isolated with the PAXgene Blood RNA Kit and purified using RNeasy MinElute

Gene expression changes induced by fluoxetine in children and adolescents

Cleanup Kit (both from Qiagen, Valencia, CA, USA). The quantity and quality of RNA was determined with a spectrophotometer (ND10-00, NanoDrop, Wilmington, OF, USA) and a Bioanalyzer (Agilent Bioanalyzer, Agilent, Santa Clara, CA, USA). A total of 1 µg of purified RNA from each of the samples was submitted to Kompetenzzentrum für Fluoreszente Bioanalytik Microarray Technology (KFB, BioPark Regensburg GmbH, Regensburg, Germany) for labelling and hybridization to Human Gene 2.1 ST Array (Affymetrix, Santa Clara, CA, USA), in accordance with the manufacturer's protocols.

Microarray data analysis

Full details of the extraction, labelling and hybridization protocols, raw array data (.cel files) and the pre-processed data matrix are available in Gene Expression Omnibus database (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE128387>).

The microarray data pre-processing analysis was performed using the Babelomics 5.0 suite (<http://www.babelomics.org/>) [25]. The data were standardized using robust multichip analysis. Multiple probes mapping to the same gene were merged using the average as the summary of the hybridization values. The sample size was not predetermined using a formal power analysis; instead it was determined based on previous estimations to identify greater than two-fold changes in gene expression levels at $P=0.01$ [26]. No data points were excluded as outliers.

Weighted correlation network analysis (WGCNA) procedure

Co-expression modules were identified using the WGCNA R software package (<https://cran.r-project.org/web/packages/WGCNA/index.html>) [27]. Co-expression analysis commences with the construction of a matrix of pairwise correlations between all pairs of genes across all selected samples. Next, the matrix is raised to a soft-thresholding power ($\beta=8$ in this study) to obtain an adjacency matrix. In order to identify modules of co-expressed genes, we constructed the topological overlap-based dissimilarity, which was then used as the input for average linkage hierarchical clustering. This step results in a clustering tree (dendrogram) whose branches are identified for cutting,

depending on their shape, using the dynamic tree-cutting algorithm. The above steps were performed using the automatic network construction and module detection function (blockwiseModules in WGCNA), with the following major parameters: minModuleSize of 30; reassign Threshold of 0; and merge CutHeight of 0.25. The modules were then tested for their associations with fluoxetine treatment by correlating module eigengenes (MEs, the first principal component of each module) with treatment status (pre- vs. post-treatment). Modules with significant ($P<0.05$) correlation were selected for further analysis. For each significant module, the correlation between the gene significance (GS, the absolute value of the Pearson correlation between each gene expression and treatment status) and its module membership (MM, the correlation between gene expression and the module eigengene at baseline) was calculated.

PPI network construction and evaluation

The SNOW program [28], implemented in the Babelomics 5.0 suite, was used to create PPI networks. If a module exceeded 500 genes (the maximum number allowed by SNOW to construct a network), to ensure higher connectivity, we selected the 500 top hub genes according to gene significance (more likely to be associated to fluoxetine treatment) and module membership (higher connectivity) values. The minimum connected network (MCN), defined as the shortest network that connects all the interacting nodes within a gene list, was obtained. Briefly, we used the curated interactome (validated by at least two independent methods) and allowed the inclusion of extra nodes that connected two or more nodes in the list. Network parameters for each gene were computed: connection degree (which accounts for the number of direct interaction partners a particular node has), clustering coefficient (which accounts for the connectivity of a given node and also for the connectivity of the neighbourhood to which this node is connected), and betweenness centrality (which is related to the existence of hubs connecting different parts of the network). Moreover, the results of the global topological values were compared with the same values of networks with the same size but made up of randomly chosen genes, and a significance value was obtained.

Gene expression changes induced by fluoxetine in children and adolescents

Gene set enrichment analysis and visualization

The MCN constructed was uploaded into Cytoscape 3.5.0 (<http://www.cytoscape.org>) [29]. We then used ClueGO v2.3.3 [30], a Cytoscape plug-in, to perform a gene set enrichment analysis (GSEA), as described previously [31]. Briefly, we selected the unstructured terms of biological processes from Gene Ontology (GO) (<http://geneontology.org/>). Genes involved in each MCN were mapped to their enriched term based on the two-sided hypergeometric test, with the Bonferroni-corrected *P*-value. ClueGO created a functional module network in which the different GO terms were clustered according to the association strength between terms calculated using chance-corrected kappa statistics.

Quantitative real-time polymerase chain reaction (Q-RT-PCR)

A Q-RT-PCR was used to verify the microarray results for two selected genes (*NAP1L2* and *ANXA1*) on a 7500 Real-Time PCR System (Applied Biosystems, Warrington, UK). *GADPH* and *ACTB* were used as endogenous controls. First, a reverse transcriptase-PCR was conducted using the “High-capacity cDNA Reverse Transcriptase” kit of Applied Biosystems, following manufacturer’s protocol. After this, the real-time RT-PCR was completed using TaqMan Gene Expression Master Mix and a TaqMan Gene Expression Assays for selected genes, following also the Applied Biosystems protocol. The genes analyzed in this study were examined for their relative expression by means of the $\Delta\Delta C_T$ method. The 32 samples analyzed by means of the microarray were validated, and each assay was performed in duplicate.

Statistical analysis

Statistical analyses were performed in SPSS version 17 (SPSS inc, Chicago, Ill). Normal distributions of the data were confirmed using Shapiro-Wilk test, and equality of the variance between groups was assessed by means of Levene’s test. For comparing two groups, a two-tailed Student’s *t* test or U-Mann Whitney was used. Significance was set at $P < 0.05$.

Results

Table 1 shows the demographic and clinical characteristics of the twenty-one study partici-

pants. In order to obtain a more homogeneous sample, we selected sixteen female samples with a diagnosis of MDD that were not taking antipsychotics and whose RNA samples had enough quality for microarray hybridization. No significant differences in clinical characteristics were detected between the whole sample and the 16 samples selected. None of the patients showed active moiety plasma levels outside the therapeutic range.

Figure 1 shows the analysis pipeline followed in the present study. Firstly, 46 modules of co-expressed genes were obtained in the WGCNA (**Figure S1**). Three modules were found to significantly correlate with fluoxetine treatment: black module (1081 genes) ($r^2=0.396$, $P=0.02$), light cyan module (383 genes) ($r^2=0.389$, $P=0.03$) and medium purple3 module (60 genes) ($r^2=-0.391$, $P=0.03$, respectively) (**Figure S2**). Black and light cyan modules were selected for further analysis, as the genes included in these modules showed a significant correlation between gene significance (GS) and module membership (MM) (black module $r^2=0.36$, $P=2 \times 10^{-34}$; light cyan module $r^2=0.48$, $P=1.83 \times 10^{-23}$; and medium purple3 $r^2=0.2$, $P=0.13$) (**Figure S3**). Lack of GS-MM correlation could indicate that only a submodule relates to the trait or suggests considering the association more tentative, needing further validation or evidence.

Secondly, genes included in the black and light cyan modules were used to construct a PPI network for each module. The MCN obtained from the black module contained 443 proteins, 193 (43.6%) of which came from the black module and 250 (56.4%) of which were added externally. The nodes of the network obtained showed more connections (connectivity degree p -value $< 1 \times 10^{-3}$), greater connectivity (clustering coefficient p -value $< 1 \times 10^{-3}$) and more hub nodes (betweenness centrality p -value $= 4 \times 10^{-4}$) compared to random expectations. The MCN from the light cyan module also presented significant values (betweenness $P < 0.001$; connectivity $P < 0.001$; and clustering coefficient < 0.001) and contained 329 genes, 138 (41.94%) of which came from the light cyan module and 191 (58.06%) that were added externally.

Finally, GSEA was performed with MCNs constructed with the black module and light cyan genes. MCNs from the black module were

Gene expression changes induced by fluoxetine in children and adolescents

Table 1. Demographic and clinical data of the study population

	Recruited sample	Microarray Sample	Statistical Test	p-value
Patients, N	21	16		
Gender, male, N (%)	2 (10.5%)	0 (0%)	–	–
Age, years (mean ± SD)	14.9 ± 1.5	14.9 ± 1.5	U=165.5	0.952
Diagnosis, N (%)			–	–
MDD	19 (90.5%)	16 (100%)	–	–
OCD	1 (4.8%)	0 (0%)	–	–
GAD	1 (4.8%)	0 (0%)	–	–
Comedication, N (%)			–	–
Antipsychotics	3 (14.29%)	0 (0%)	–	–
Benzodiazepines	5 (23.8%)	5 (31.25%)	–	–
Baseline, score (mean ± SD)				
GAF/CGAS	44.8 ± 9.2	45.38 ± 8.14	U=162.0	0.865
CGI-S	4.5 ± 0.8	4.38 ± 0.62	U=162.5	0.881
CDI	27.1 ± 11	29.2 ± 8.6	t=-0.613	0.272
OCI-CV	15.0 ± 8.2	15.75 ± 7.9	t=-0.295	0.384
SCARED	34.2 ± 14.8	38 ± 12.7	t=-0.823	0.208
8 weeks, score (mean ± SD)				
GAF/CGAS	55.7 ± 12.6	56.6 ± 13.6	U=141.5	0.741
CGI-S	3.7 ± 0.9	3.6 ± 11.8	U=144.5	0.818
CDI	23.6 ± 13.2	24.7 ± 11.8	t=-0.794	0.219
OCI-CV	16.3 ± 9.8	16.8 ± 10.2	t=-0.146	0.442
SCARED	34.1 ± 15.7	35.8 ± 15.3	t=-0.324	0.756
Fluoxetine 8 weeks, ng/mL (mean ± SD)	123.68 ± 71.3	121.81 ± 71.92	t=0.078	0.469
Norfluoxetine 8 weeks, ng/mL (mean ± SD)	154.63 ± 74.02	159.88 ± 73.32	t=-0.207	0.418
FLU+NORFLU 8 weeks, ng/mL (mean ± SD)	278.31 ± 113.997	281.69 ± 110.62	t=-0.086	0.466

enriched with 336 GO biological process terms merged in a network that included 51 clusters (**Figure 2A**) ([Table S1](#)). These clusters were involved in cellular processes (12 clusters, 23.53%), metabolic processes (10 clusters, 19.60%), cell communication (8 clusters, 15.68%), immune system processes (6 clusters, 11.76%), protein localization and transport (6 clusters, 11.76%), cell death (6 clusters, 11.76%), response to stimulus (5 clusters, 9.80%) and neurogenesis (2 clusters, 3.92%). MCN from light cyan was enriched with a network of 192 terms in 32 clusters (**Figure 2B**) ([Table S2](#)). Regarding the light cyan module, the clusters related mainly to immune system processes (8 clusters, 25% of the genes), metabolic processes (7 clusters, 21.87%), response to stimulus (6 clusters, 18.75%), cellular metabolic processes (5 clusters, 15.62%), cell communication (5 clusters, 15.62%), neurogenesis (4 clusters, 12.5%), protein localization and transport (2 clusters, 6.25%) and cell death (2 clusters, 6.25%). These biological GO processes

were similar across the two networks, since they had 117 in common (35% black and 41% light cyan). These 117 processes belonged to 33 clusters in the black module (64.7%) and 26 clusters in the light cyan module (81.25%). Out of these 117 processes, most were involved in the same functions as clusters of individual networks: cellular metabolic processes (29.91%), metabolic processes (16.24%), cell communication (11.96%), localization (11.11%), immune system processes (7.69%), cell death (5.98%), neurogenesis (5.13%) and response to stimulus (4%). We compared the lists of the two modules and analysed the over-representation of GO biological processes, but no significant processes were observed.

Two genes (*NAP1L2* and *ANXA1*) were selected for further validation using quantitative RT-PCR evaluation. These genes were chosen based on the following criteria: 1) each of them belonged to a different GO category (Neurogenesis and Immune system); 2) their expression was

Gene expression changes induced by fluoxetine in children and adolescents




Figure 1. Analysis workflow followed in the present study. Briefly, 21 child and adolescences were recruited, and blood samples were collected before treatment initiation and after eight weeks of fluoxetine treatment. 16 patients participated in the gene expression study. WGCNA identified 46 modules of co-expressed genes, two significantly associated with fluoxetine treatment. PPI were constructed from the significant modules, and GSEA was performed to provide functional interpretation.

altered significantly after fluoxetine treatment ($P < 0.05$); and 3) each of them had central role in PPI network. As can be seen in **Figure 3**, the genes analyzed were clearly validated, as they exhibited an identical pattern of expression, without significant differences between both methodologies according to ANOVA test.

Discussion

We propose a systems biology analytical approach, based on the identification of gene co-

expression modules followed by protein-protein interaction network construction and functional annotation analysis, of changes in gene expression induced by eight weeks of treatment with fluoxetine in peripheral blood of drug-naïve children and adolescents. The main objective of the present study was to identify key biological processes involved in fluoxetine response. These processes could be a possible source of peripheral biomarkers of fluoxetine treatment or candidate genes for pharmacogenetic studies of the fluoxetine response. Our findings replicate previous results that support the role of the inflammatory system in the antidepressant response. And, for the first time in the literature, we identified processes related to neurogenesis in the peripheral blood of children and adolescents as possible biomarkers of antidepressant treatment.

As previously mentioned, some genome-wide gene expression studies of SSRI have used WGCNA [8, 14]. However, our study presents some differences with respect to those studies. Firstly, our study was performed in a sample of children and adolescents. This represents a homogeneous sample because the onset of the illness was in childhood. Age at onset is an important trait in

mental illnesses, and sometimes even defines subgroups of patients with different clinical traits and outcomes [32-35]. Moreover, our patients were debuting or in the initial phases of the illness, and confounders relating to disease progression or chronicity were avoided. Lastly, they were naive patients, and therefore there were no confounders related to previous drug treatment. Studies by Hodgson et al. (2016) [14] and Belzeaux et al. (2016) [15] used larger samples, but these were more heterogeneous in terms of age of onset. We also

Gene expression changes induced by fluoxetine in children and adolescents




Figure 2. Functional network of Gene Ontology (GO) biological processes obtained from each PPI network, according to ClueGO: black module (A) and light cyan module (B). Each node represents a GO biological process. The node size represents the enriched *p*-value corrected with the Benjamini-Hochberg method. Edge between nodes based on their kappa score level. Nodes were grouped in clusters represented by different colors. Clusters were related to common processes represented by circles. Legends listed all clusters and grouped related clusters according to common biological process.

analysed fluoxetine and non-fluoxetine plasma levels to ensure that they were within therapeutic levels and that the results were not biased due to a lack of adherence in some patients. Secondly, our study focused on fluoxetine. Bezeaux's study [15] analyzed the effect of citalo-

pram, and Hodgson's study [14] examined the effects of the SSRI escitalopram and the tricyclic antidepressant nortriptyline. Another aspect to consider is that, in our study and the study by Hodgson et al. (2016) [14] the follow-up period was eight weeks of treatment, where-

Gene expression changes induced by fluoxetine in children and adolescents




Figure 3. Results of the quantitative real-time PCR (using *GADPH* or *ACTB* as endogenous controls) and microarray analysis for validation of selected genes (*NAP1L2* and *ANXA1*). Each value is the mean \pm SD of 32 values; duplicate measurements of 16 biological replicates for each condition (pre- and post-treatment). The Y-axis shows the fold-change (treated vs. untreated) from both Q-RT-PCR and microarray.

as in the study by Belzeaux et al. (2016) [15], it was 12 weeks. Finally, although the three studies used WGCNA, the functional genomic analysis of the significant modules in each study was slightly different. Moreover, Hodgson et al. (2016) [14] focused on molecular knowledge, and used molecular functions and cellular component categories of GO instead of biological processes. By contrast, Belzeaux et al. (2016) [15] focused on GO categories of biological processes and regulation by mi-RNAs. We performed an analysis of GO biological processes, not directly in the genes belonging to significant modules, but in the MCNs created from these significant modules.

The study by Belzeaux et al. (2016) [15] identified 59 modules, nine of which were associated with the citalopram response. Interestingly, four of these significant modules were related to the immune system. In our study, the two significant modules showed enrichment of biological processes related to the immune system, thus supporting the hypothesis that the inflammatory state plays a role in the antidepressant response [36]. Immune system is highly implied in mental illness [37]: in mood and anxiety disorders [38], bipolar disorder [39], obsessive compulsive disorder [40], autism spectrum disorders [41], even in psychosis spectrum disor-

ders [42, 43] and in alzheimer and dementia [44-46]. Specifically, inflammatory response are involved in the neuroprogression of MDD. Moreover, these inflammatory mediators have been investigated as putative biomarkers and therapeutic targets for MDD [47, 48]. Concerning SSRI response, the main SSRI target, the serotonin transporter, is regulated by proinflammatory cytokines [49, 50]. Studies in both, cell cultures [51] and animal models [52-54], showed modulation of inflammatory mediators and immune responses by antidepressants.

In humans, many studies have demonstrated that immune alterations related with MDD, such as levels of some interleukines, cytokines or interferons

(i.e. IL-6, TNF- α , and IL-1 β), may return to normal in MDD patients after treatment with SSRIs and with other antidepressants [48, 55]. Hodgson et al. (2016) [14] identified 10 modules of co-expression genes, one of which was significantly correlated with fluoxetine treatment. This module was enriched with five GO molecular categories linked to Mrna-UTR binding and with the cellular component of the cortical cytoskeleton [14]. Cytoskeletal reorganization is an important event during neurogenesis, a process identified in our significant modules. During development, neural progenitor cells begin a series of morphological changes to adapt their form, migrate to their destination and create synapses [56, 57]. Neurogenesis is a mechanism that has previously been related to mental illness [58-60], including MDD [61], OCD [62] and anxiety [63]. Several studies have demonstrated that neurogenesis processes are involved in the SSRI response using both cell cultures [64, 65] and animal models [66-68]. In humans, it has been demonstrated that the hippocampal volume is decreased in patients with MDD when compared to controls [69, 70]. Patients treated with antidepressants have shown an increased hippocampal volume, and this increase correlates with a better clinical outcome [71, 72].

Limitations

It is important to treat the results of this study with caution, because it presents some unavoidable limitations. First, blood was used as a proxy for the key tissue of interest in antidepressant research, i.e. the brain. Studies that explore the degree of gene co-expression in blood and brain in humans suggest that there is a moderate correlation [73-76]. Nevertheless, other sample types, such as post-mortem brain tissue, prevent biological measurements from being taken before and after treatment [77]. Second, no placebo or control group was used. Both of these groups would have allowed us to distinguish the response to antidepressants, the response to placebo, and the spontaneous improvement of symptoms [78]. Third, the biological validity of gene co-expression modules was not fully explored. Co-expressed genes are supposed to be correlated because of common biological functions and master regulators, not random ones [79]. Fourth, the sample size did not allow us to stratify the sample by different psychiatric illnesses, thereby making it impossible to capture differences. Moreover, it meant that we had to indicate that these results were exploratory.

Conclusions

Expression changes detected in peripheral blood after treatment with fluoxetine in a sample of naive children and adolescents were found to be related to several biological processes. The processes related to immune system replicated previous findings in the literature using similar approaches. We identified neurogenesis for the first time by measuring expression changes in peripheral blood. This makes sense from a biological point of view, as this is a mechanism proposed to be involved in fluoxetine response. Our results identifying several biological processes in relation to fluoxetine treatment in peripheral blood, offering new candidate genes for pharmacogenetic studies and valuable markers for peripheral moderator biomarkers discovery.

Acknowledgements

This work was supported by the Alicia Koplowitz Foundation; the Spanish Ministry of Health, Instituto Carlos III, Fondo de Investigación Sanitaria (FIS) (PI16/O1086); and FEDER-Unión

Europea. Support was also given by the “Agència de Gestió d'Ajuts Universitaris i Recerca” (AGAUR) of the “Generalitat de Catalunya” to the “Child Psychiatry and Psychology Group” (2017SGR881) and to the “Clinical Pharmacology and Pharmacogenetics Group” (2017-SGR1562). The authors thank all subjects and their families for the time and effort spent on this study. The authors also thank A.M. for sample collection assistance and P.M. for his help with technical problems.

Disclosure of conflict of interest

None.

Abbreviations

CPIC, Clinical Pharmacogenetics Implementation Consortium; CDI, Children's Depression Inventory; CGAS, Children's Global Assessment Scale; CGI-S, Clinical Global Impression Severity scale; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; FLX, Fluoxetine; GAD, Generalized Anxiety Disorder; GAF, Global Assessment of Functioning; GSEA, Gene Set Enrichment Analysis; GWAs, Genome-Wide Association Studies; MCN, Minimum Connected Network; MDD, Major Depressive Disorder; NORFLX, Norfluoxetine; OCD, Obsessive Compulsive Disorder; PPI, Protein-Protein interaction; SCARED, Screen for Child Anxiety-Related Emotional Disorders; SNPs, Single Nucleotide Polymorphisms; WGCNA, Weighted Correlation Network Analysis.

Address correspondence to: Drs. Sergi Mas and Joan Albert Arnaiz, Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, IDIBAPS, Casanova 143, E-08036 Barcelona, Spain. Tel: 0034934024526; Fax: 0034934035881; E-mail: sergimash@ub.edu (SM); jaarnaiz@clinic.ub.es (JAA)

References

- [1] Mrazek DA, Biernacka JM, McAlpine DE, Benitez J, Karpyak VM, Williams MD, Hall-Flavin DK, Netzel PJ, Passov V, Rohland BM, Shinzaki G, Hoberg AA, Snyder KA, Drews MS, Skime MK, Sagen JA, Schaid DJ, Weinshilboum R and Kitzelnick DJ. Treatment outcomes of depression: the pharmacogenomic research network antidepressant medication pharmacogenomic study. *J Clin Psychiatry* 2015; 34: 313-317.

Gene expression changes induced by fluoxetine in children and adolescents

- [2] Tansey KE, Guipponi M, Hu X, Domenici E, Lewis G, Malafosse A, Wendland JR, Lewis CM, McGuffin P and Uher R. Contribution of common genetic variants to antidepressant response. *Biol Psychiatry* 2013; 73: 679-682.
- [3] Brown JT, Bishop JR, Sangkuhl K, Nurmi EL, Mueller DJ, Dinh JC, Gaedigk A, Klein TE, Caudle KE, McCracken JT, de Leon J and Leeder JS. Clinical pharmacogenetics implementation consortium guideline for cytochrome P450 (CYP)2D6 genotype and atomoxetine therapy. *Clin Pharmacol Ther* 2019; 106: 94-102.
- [4] Fabbri C and Serretti A. Clinical application of antidepressant pharmacogenetics: considerations for the design of future studies. *Neurosci Lett* 2018: 133651.
- [5] Amare AT, Schubert KO and Baune BT. Pharmacogenomics in the treatment of mood disorders: strategies and opportunities for personalized psychiatry. *EPMA J* 2017; 8: 211-227.
- [6] Biernacka JM, Sangkuhl K, Jenkins G, Whaley RM, Barman P, Batzler A, Altman RB, Arolt V, Brockmüller J, Chen CH, Domschke K, Hall-Flavin DK, Hong CJ, Illi A, Ji Y, Kampman O, Kinoshita T, Leinonen E, Liou YJ, Mushiroda T, Nonen S, Skime MK, Wang L, Baune BT, Kato M, Liu YL, Praphanphoj V, Stingl JC, Tsai SJ, Kubo M, Klein TE and Weinshilboum R. The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response. *Transl Psychiatry* 2015; 5: 1-9.
- [7] Fabbri C, Kasper S, Kautzky A, Bartova L, Dold M, Zohar J, Souery D, Montgomery S, Albani D, Raimondi I, Dikeos D, Rujescu D, Uher R, Lewis CM, Mendlewicz J and Serretti A. Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples. *Br J Psychiatry* 2019; 214: 36-41.
- [8] Belzeaux R, Lin R, Ju C, Chay MA, Fiori LM, Lutz PE and Turecki G. Transcriptomic and epigenomic biomarkers of antidepressant response. *J Affect Disord* 2017; 233: 36-44.
- [9] Guilloux JP, Bassi S, Ding Y, Walsh C, Turecki G, Tseng G, Cyranowski JM and Sibille E. Testing the predictive value of peripheral gene expression for nonremission following citalopram treatment for major depression. *Neuropsychopharmacology* 2014; 40: 701-710.
- [10] Hennings JM, Uhr M, Klengel T, Weber P, Pütz B, Touma C, Czamara D, Ising M, Holsboer F and Lucae S. RNA expression profiling in depressed patients suggests retinoid-related orphan receptor alpha as a biomarker for antidepressant response. *Transl Psychiatry* 2015; 5: e538.
- [11] Mamdani F, Berlim MT, Beaulieu MM, Labbe A, Merette C and Turecki G. Gene expression biomarkers of response to citalopram treatment in major depressive disorder. *Transl Psychiatry* 2011; 1: e13.
- [12] Belzeaux R, Bergon A, Jeanjean V, Loriod B, Formisano-Tréziny C, Verrier L, Loundou A, Baumstarck-Barrau K, Boyer L, Gall V, Gabert J, Nguyen C, Azorin JM, Naudin J and Ibrahim E. Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode. *Transl Psychiatry* 2012; 2: e185.
- [13] Pettai K, Milani L, Tammiste A, Võsa U, Kolde R, Eller T, Nutt D, Metspalu A and Maron E. Whole-genome expression analysis reveals genes associated with treatment response to escitalopram in major depression. *Eur Neuropsychopharmacol* 2016; 26: 1475-1483.
- [14] Hodgson K, Tansey KE, Powell TR, Coppola G, Uher R, Zvezdana Dernovsek M, Mors O, Hauser J, Souery D, Maier W, Henigsberg N, Rietschel M, Placentino A, Aitchison KJ, Craig IW, Farmer AE, Breen G, McGuffin P and Dobson R. Transcriptomics and the mechanisms of antidepressant efficacy. *Eur Neuropsychopharmacol* 2016; 26: 105-112.
- [15] Belzeaux R, Lin CW, Ding Y, Bergon A, Ibrahim EC, Turecki G, Tseng G and Sibille E. Predisposition to treatment response in major depressive episode: a peripheral blood gene co-expression network analysis. *J Psychiatr Res* 2016; 81: 119-126.
- [16] American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. Washington, DC; 1994.
- [17] Luborsky L. Clinician's judgments of mental health. *Arch Gen Psychiatry* 1962; 7: 407-417.
- [18] Shaffer D, Brasic J, Ambrosini P, Fisher P, Bird H and Aluwahlia S. A children's global assessment scale (cgas). *Arch Gen Psychiatry* 1983; 40: 1228-1231.
- [19] Busner J and Targum SD. Global impressions scale: applying a research. *Psychiatry (Edgmont)* 2007; 4: 28-37.
- [20] Kovacs M. Coddington life events scales (CLES) conners' rating scales-revised (CRS-R) diagnostic interview for children and adolescents-IV (DICA-IV™) feelings, attitudes, and behaviors scales for children (FAB-C) internalized shame scale (ISS) multidimensional an. *MHS* 1992; 1-3.
- [21] Jones AM, De Nadai AS, Arnold EB, McGuire JF, Lewin AB, Murphy TK and Storch EA. Psychometric properties of the obsessive compulsive inventory: child version in children and adolescents with obsessive-compulsive disorder. *Child Psychiatry Hum Dev* 2013; 44: 137-151.
- [22] Birmaher B, Khetarpal S, Brent D, Cully M, Balach L, Kaufman J and Neer SM. The screen for child anxiety related emotional disorders

Gene expression changes induced by fluoxetine in children and adolescents

- (SCARED): scale construction and psychometric characteristics. *J Am Acad Child Adolesc Psychiatry* 2003; 36: 545-553.
- [23] LLerena A, Dorado P, Berecz R, Gonzalez A, Jesus Norberto M, De La Rubia A and Caceres M. Determination of fluoxetine and norfluoxetine in human plasma by high-performance liquid chromatography with ultraviolet detection in psychiatric patients. *J Chromatogr B Anal Technol Biomed Life Sci* 2003; 783: 25-31.
- [24] Hiemke C and Hartter S. Pharmacokinetics of selective serotonin reuptake inhibitors. *Pharmacol Ther* 2000; 85: 11-28.
- [25] Alonso R, Salavert F, Garcia-Garcia F, Carbonell-Caballero J, Bleda M, Garcia-Alonso L, Sanchis-Juan A, Perez-Gil D, Marin-Garcia P, Sanchez R, Cubuk C, Hidalgo MR, Amadoz A, Hernansaiz-Ballesteros RD, Alemán A, Tarraga J, Montaner D, Medina I and Dopazo J. Babelomics 5.0: functional interpretation for new generations of genomic data. *Nucleic Acids Res* 2015; 43: 117-121.
- [26] Wei C, Li J and Bumgarner RE. Sample size for detecting differentially expressed genes in microarray experiments. *BMC Genomics* 2004; 10: 1-10.
- [27] Langfelder P and Horvath S. WGCNA: an R package for weighted correlation network analysis. *BMC Bioinformatics* 2008; 9: 559.
- [28] Minguez P, Götz S, Montaner D, Al-Shahrour F and Dopazo J. SNOW, a web-based tool for the statistical analysis of protein-protein interaction networks. *Nucleic Acids Res* 2009; 37: 109-114.
- [29] Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res* 2003; 13: 2498-2504.
- [30] Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, Fridman W, Pagès F, Trajanoski Z and Galon J. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. *Bioinformatics* 2009; 25: 1091-1093.
- [31] Mas S, Gassó P, Parellada E, Bernardo M and Lafuente A. Network analysis of gene expression in peripheral blood identifies mTOR and NF- κ B pathways involved in antipsychotic-induced extrapyramidal symptoms. *Pharmacogenomics J* 2015; 15: 452-60.
- [32] de Girolamo G, McGorry PD and Sartorius N. Relevance of the age of onset of mental disorders to research in psychiatry and to the organization of services for people with mental illness. In: age of onset of mental disorders. Cham: Springer International Publishing; 2019. pp. 1-13.
- [33] Yalin N and Young AH. The age of onset of unipolar depression. In: de Girolamo G, McGorry PD and Sartorius N, editors. Age of onset of mental disorders: etiopathogenetic and treatment implications. Cham: Springer International Publishing; 2019. pp. 111-124.
- [34] Legerstee JS, Dierckx B, Utens EMWJ, Verhulst FC, Zieldorff C, Dieleman GC and de Lijster JM. The age of onset of anxiety disorders BT - age of onset of mental disorders: etiopathogenetic and treatment implications. In: de Girolamo G, McGorry PD and Sartorius N, editors. Cham: Springer International Publishing; 2019. pp. 125-147.
- [35] Sharma E, Sundar AS, Thennarasu K and Reddy YC. Is late-onset OCD a distinct phenotype? Findings from a comparative analysis of "age at onset" groups. *CNS Spectr* 2015; 20: 508-14.
- [36] Anderson G and Maes M. How immune-inflammatory processes link CNS and psychiatric disorders: classification and treatment implications. *CNS Neurol Disord Drug Targets* 2017; 16: 266-278.
- [37] Miller AH, Haroon E and Felger JC. The immunology of behavior-exploring the role of the immune system in brain health and illness. *Neuropsychopharmacology* 2017; 42: 1-4.
- [38] Bennett FC and Molofsky AV. The immune system and psychiatric disease: a basic science perspective. *Clin Exp Immunol* 2019; 197: 294-307.
- [39] Niu Z, Yang L, Wu X, Zhu Y and Chen J. The relationship between neuroimmunity and bipolar disorder: mechanism and translational application. *Neurosci Bull* 2019; 35: 595-607.
- [40] Marazziti D, Mucci F and Fontenelle LF. Psychoneuroendocrinology Immune system and obsessive-compulsive disorder. *Psychoneuroendocrinology* 2018; 93: 39-44.
- [41] Masi A, Glozier N, Dale R and Guastella AJ. The immune system, cytokines, and biomarkers in autism spectrum disorder. *Neurosci Bull* 2017; 33: 194-204.
- [42] van Mierlo HC, Schot A, Boks MPM and de Witte LD. The association between schizophrenia and the immune system: review of the evidence from unbiased 'omic-studies'. *Schizophr Res* 2019; [Epub ahead of print].
- [43] Radhakrishnan R, Kaser M and Guloksuz S. The link between the immune system, environment, and psychosis. *Schizophr Bull* 2017; 43: 693-697.
- [44] Cao W and Zheng H. Peripheral immune system in aging and Alzheimer's disease. *Mol Neurodegener* 2018; 13: 51.
- [45] Busse M, Michler E, Dobrowolny H, Hartig R, Frodl T and Busse S. Alterations in the periph-

Gene expression changes induced by fluoxetine in children and adolescents

- eral immune system in dementia. *J Alzheimers Dis* 2017; 58: 1303-1313.
- [46] Jevtic S, Sengar AS, Salter MW and McLaurin J. The role of the immune system in Alzheimer disease: etiology and treatment. *Ageing Res Rev* 2017; 40: 84-94.
- [47] Lichtblau N, Schmidt FM, Schumann R, Kirkby KC and Himmerich H. Cytokines as biomarkers in depressive disorder: current standing and prospects. *Int Rev Psychiatry* 2013; 25: 592-603.
- [48] Slyepchenko A, Maes M, Köhler CA, Anderson G, Quevedo J, Alves GS, Berk M, Fernandes BS and Carvalho AF. T helper 17 cells may drive neuroprogression in major depressive disorder: proposal of an integrative model. *Neurosci Biobehav Rev* 2016; 64: 83-100.
- [49] Malynn S, Campos-Torres A, Moynagh P and Haase J. The pro-inflammatory cytokine TNF- α regulates the activity and expression of the serotonin transporter (SERT) in astrocytes. *Neurochem Res* 2013; 38: 694-704.
- [50] Zhu C, Blakely RD and Hewlett WA. The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. *Neuropsychopharmacology* 2006; 31: 2121-31.
- [51] Tynan RJ, Weidenhofer J, Hinwood M, Cairns MJ, Day TA and Walker FR. A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. *Brain Behav Immun* 2012; 26: 469-479.
- [52] Benatti C, Alboni S, Blom JMC, Mendlewicz J, Tasciedda F and Brunello N. Molecular changes associated with escitalopram response in a stress-based model of depression. *Psychoneuroendocrinology* 2018; 87: 74-82.
- [53] Nazimek K, Kozłowski M, Bryniarski P, Strobel S, Bryk A, Myszk A, Tyszka A, Kuzmiersz P, Nowakowski J and Filipczak-Bryniarska I. Repeatedly administered antidepressant drugs modulate humoral and cellular immune response in mice through action on macrophages. *Exp Biol Med (Maywood)* 2016; 241: 1540-50.
- [54] Gevorgyan MM, Idova GV, Al'perina EL, Tikhonova MA and Kulikov AV. Effect of antidepressants on immunological reactivity in ASC mice with genetically determined depression-like state. *Bull Exp Biol Med* 2016; 161: 266-269.
- [55] Mikova O, Yakimova R, Bosmans E, Kenis G and Maes M. Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. *Eur Neuropsychopharmacol* 2001; 11: 203-208.
- [56] Compagnucci C, Piemonte F, Bertini E, Sferra A and Piermarini E. The cytoskeletal arrangements necessary to neurogenesis. *Oncotarget* 2016; 7: 19414-19429.
- [57] Akiyama H and Sakakibara S. Cytoskeletons in neuronal development. *J Phys Fit Sport Med* 2016; 5: 131-142.
- [58] Kang E, Wen Z, Song H, Christian KM and Ming GL. Adult neurogenesis and psychiatric disorders. *Cold Spring Harb Perspect Biol* 2016; 8.
- [59] Apple DM, Fonseca RS and Kokovay E. The role of adult neurogenesis in psychiatric and cognitive disorders. *Brain Res* 2017; 1655: 270-276.
- [60] Micheli L, Ceccarelli M, D'Andrea G and Tirone F. Depression and adult neurogenesis: positive effects of the antidepressant fluoxetine and of physical exercise. *Brain Res Bull* 2018; 143: 181-193.
- [61] Boku S, Nakagawa S, Toda H and Hishimoto A. Neural basis of major depressive disorder: beyond monoamine hypothesis. *Comput Graph Forum* 2018; 37: 3-12.
- [62] van de Vondervoort I, Poelmans G, Aschrafi A, Pauls DL, Buitelaar JK, Glennon JC and Franke B. An integrated molecular landscape implicates the regulation of dendritic spine formation through insulin-related signalling in obsessive-compulsive disorder. *J Psychiatry Neurosci* 2016; 41: 280-285.
- [63] Kheirbek MA and Hen R. Add neurons, subtract anxiety. *Mazen. Sci Am* 2014; 71: 3831-3840.
- [64] Ghareghani M, Zibara K, Sadeghi H, Dokoohaki S, Sadeghi H, Aryanpour R and Ghanbari A. Fluvoxamine stimulates oligodendrogenesis of cultured neural stem cells and attenuates inflammation and demyelination in an animal model of multiple sclerosis. *Sci Rep* 2017; 7: 1-18.
- [65] Chang KA, Kim JA, Kim S, Joo Y, Shin KY, Kim S, Kim HS and Suh YH. Therapeutic potentials of neural stem cells treated with fluoxetine in Alzheimer's disease. *Neurochem Int* 2012; 61: 885-891.
- [66] Malberg JE, Eisch AJ, Nestler EJ and Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. *J Neurosci* 2000; 20: 9104-9110.
- [67] Hodes GE, Hill-Smith TE and Lucki I. Fluoxetine treatment induces dose dependent alterations in depression associated behavior and neural plasticity in female mice. *Neurosci Lett* 2010; 484: 12-16.
- [68] Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O, Hen R and Belzung C. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. *Science* 2003; 301: 805-809.
- [69] Bremner JD, Narayan M, Anderson ER, Staib LH, Miller HL and Charney DS. Hippocampal volume reduction in major depression. *Am J Psychiatry* 2000; 157: 115-117.

Gene expression changes induced by fluoxetine in children and adolescents

- [70] Videbech P and Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. *Am J Psychiatry* 2004; 161: 1957-1966.
- [71] Vermetten E, Vythilingam M, Southwick SM, Charney DS and Bremner JD. Long-term treatment with paroxetine increases verbal declarative memory and hippocampal volume in post-traumatic stress disorder. *Biol Psychiatry* 2003; 54: 693-702.
- [72] Frodl T, Meisenzahl EM, Zetzsche T, Höhne T, Banac S, Schorr C, Jäger M, Leinsinger G, Böttlinger R, Reiser M and Möller HJ. Hippocampal and amygdala changes in patients with major depressive disorder and healthy controls during a 1-year follow-up. *J Clin Psychiatry* 2004; 65: 492-499.
- [73] Cai C, Langfelder P, Fuller TF, Oldham MC, Luo R, van den Berg LH, Ophoff RA and Horvath S. Is human blood a good surrogate for brain tissue in transcriptional studies? *BMC Genomics* 2010; 11: 589-604.
- [74] Lunnon K, Ibrahim Z, Proitsi P, Lourdasamy A, Newhouse S, Sattler M, Furney S, Saleem M, Soininen H, Kłoszewska I, Mecocci P, Tsolaki M, Vellas B, Coppola G, Geschwind D, Simmons A, Lovestone S, Dobson R and Hodges A; AddNeuroMed Consortium. Mitochondrial dysfunction and immune activation are detectable in early alzheimer's disease blood. *J Alzheimers Dis* 2012; 30: 685-710.
- [75] Sullivan PF, Fan C and Perou CM. Evaluating the comparability of gene expression in blood and brain. *Am J Med Genet B Neuropsychiatr Genet* 2006; 141B: 261-8.
- [76] Liew CC, Ma J, Tang HC, Zheng R and Dempsey AA. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. *J Lab Clin Med* 2006; 147: 126-132.
- [77] Menke A, Klengel T, Rubel J, Bruckl T, Pfister H, Lucae S, Uhr M, Holsboer F and Binder E. Genetic variation in FKBP5 associated with the extent of stress hormone dysregulation in major depression. *Genes Brain Behav* 2013; 12: 289-296.
- [78] Hall KT and Kaptchuk TJ. Genetic biomarkers of placebo response: what could it mean for future trial design? *Clin Investig* 2014; 71: 3831-3840.
- [79] Gaiteri C, Ding Y, French B, Tseng GC and Sibille E. Beyond modules and hubs: the potential of gene coexpression networks for investigating molecular mechanisms of complex brain disorders. *Genes Brain Behav* 2013; 13: 13-24.




Figure S1. Gene co-expression networks obtained in the WGCNA. Branches in the hierarchical clustering dendrograms correspond to modules. Modules of co-expressed genes were assigned colours corresponding to the branches.

Gene expression changes induced by fluoxetine in children and adolescents




Figure S2. Correlation and significance of module eigengenes (MEs, the first principal component of each module) identified in the WGCNA with treatment status (pre- vs. post-treatment).

Gene expression changes induced by fluoxetine in children and adolescents




Figure S3. Representation of correlation between the gene significance for treatment status and its membership in the module. Only significant WGCNA modules are shown.